Robenacoxib versus meloxicam for the control of peri-operative pain and inflammation associated with orthopaedic surgery in cats: a randomised clinical trial

Table 6 Summary statistics for the clinician efficacy scores in the first 24 hours after surgery

Response	Visits	Robenacoxib (s.c. + oral)	Meloxicam s.c. + oral placebo	P value (Mann–Whitney test)	Quotient robenacoxib:meloxicam (RMANCOVA)		P value (RMANCOVA)	Transformation for RMANCOVA analysis
		Mean (SD)	Mean (SD)		Mean	95% CI		Transformation	P value for normality (Shapiro-Wilks test)
Global investigator score (primary end point)	V2-V4	2.72 (1.42)	2.80 (1.62)	0.76	1.029	0.847–1.231	0.76	0 (log)	0.20
Posture	V2-V4	0.68 (0.53)	0.79 (0.61)	0.38	1.144	0.821–1.538	0.39	−1 (reciprocal)	<0.0001
Behaviour	V2-V4	0.81 (0.56)	0.88 (0.64)	0.91	1.073	0.827–1.360	0.58	−0.5 (reciprocal of square root)	0.024
Pain on palpation/manipulation	V2-V4	1.22 (0.69)	1.14 (0.69)	0.23	0.979	0.799–1.184	0.82	0.5 (square root)	0.0024
Overall pain control	V2-V4	1.17 (0.76)	1.15 (0.67)	0.89	1.120	0.880–1.408	0.34	0.5 (square root)	0.011
Sedation	V2-V4	0.44 (0.44)	0.40 (0.42)	0.76	0.945	0.396–1.755	0.85	−0.5 (reciprocal of square root)	0.024

CI: confidence interval; s.c.: subcutaneous.
Values are mean (SD) for each group and quotient values with 95% CIs for the ratio robenacoxib/meloxicam. Data are from the assessments at V2, V3 and V4. Non-inferiority of robenacoxib versus meloxicam was concluded if the lower limit of the 95% CI was >0.75 (shown in bold). P values <0.05 are also shown in bold.
The global investigator score (the primary end point) ranged from 0 to 9. All other end points (secondary end points) ranged from 0 to 3.

ISSN: 1746-6148